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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by upper and lower motoneuron death.
Mutations in the gene for superoxide dismutase 1 (SOD1) cause a familial form of ALS and have been used to develop transgenic
mice which overexpress human mutant SOD1 (mSOD) and these mice exhibit a motoneuron disease which is pathologically and
phenotypically similar to ALS. Neuroinflammation is a pathological hallmark of many neurodegenerative diseases including ALS
and is typified by the activation and proliferation ofmicroglia and the infiltration of T cells into the brain and spinal cord. Although
the neuroinflammatory response has been considered a consequence of neuronal dysfunction and death, evidence indicates that
manipulation of this response can alter disease progression. Previously viewed as deleterious to neuronal survival, recent reports
suggest a trophic role for activated microglia in the mSODmouse during the early stages of disease that is dependent on instructive
signals from infiltrating T cells. However, at advanced stages of disease, activated microglia acquire increased neurotoxic potential,
warranting further investigation into factors capable of skewingmicroglial activation towards a neurotrophic phenotype as ameans
of therapeutic intervention in ALS.
1. Introduction
Neuroinflammation is a pathological hallmark of many neu-
rodegenerative diseases including Alzheimer’s disease (AD),
Parkinson’s disease (PD), and amyotrophic lateral sclerosis
(ALS). It is characterized by the activation and prolifera-
tion of microglia (microgliosis) and the accumulation of
infiltrating T lymphocytes at sites of neurodegeneration.
Although often considered a consequence to neuronal injury
and degeneration, the neuroinflammatory response can have
protective or deleterious eﬀects on neuronal survival. These
disparate eﬀects are elicited by the heterogeneous activation
programs of microglia, which in turn are dictated by their
surrounding microenvironment and by infiltrating T cells.
2. Amyotrophic Lateral Sclerosis
and the mSOD Mouse Model
Typically diagnosed during the fifth decade of life, amy-
otrophic lateral sclerosis (ALS) is a fatal neurodegenerative
disease characterized by the degeneration of motoneurons
in the brainstem and spinal cord and loss of descending
motor tracts. Clinical manifestations of ALS include muscle
weakness, spasticity, muscle atrophy, and advancing paralysis
that culminates in respiratory failure, the usual cause of
death in aﬀected patients. ALS is a disease primarily of
sporadic etiology with a plethora of aberrant physiological
processes implicated in its pathogenesis including excitotoxi-
city, oxidative damage, the formation protein aggregates, and
mitochondrial dysfunction [1]. A pathological hallmark of
sporadic ALS is the presence of cytoplasmic ubiquitinated
protein inclusions in aﬀected areas of the brain and spinal
cord that are predominantly composed of the TDP-43 (trans-
active response DNA-binding protein 43), an RNA/DNA-
binding protein normally found in the nucleus [2].
A small fraction of cases (∼10%) termed familial ALS
(fALS) are due to a variety of genetic mutations, with
20% of fALS cases due to dominantly inherited mutations
in superoxide dismutase 1 (SOD1). SOD1 is a ubiqui-
tously expressed, 32 kDa homodimeric cytosolic protein that
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catalyzes the dismutation of superoxide, a by-product of
cellular respiration, to hydrogen peroxide. To date, over 125
diﬀerent mutations that span the entire genomic sequence
and protein structure of SOD1 have been identified as
causing ALS [3]. In 1994, Gurney et al. [4] developed
transgenic mice that overexpress mutant SOD1 (mSOD) and
develop a progressive motoneuron degeneration resembling
ALS, including cytoplasmic mislocalization of TDP-43 at
end-stage of disease [5]. However, after years of investigation,
the pathogenic basis of mSOD remains elusive. The majority
of SOD1 mutants retain at least partially normal enzyme
activity and ablation of the murine SOD1 gene does not
culminate in motoneuron pathology [6], indicating that
the pathogenic nature of mSOD is through a toxic gain of
function rather than a loss of function. Several pathogenic
mechanisms of mSOD have been suggested including an
increased propensity to form intracellular aggregates, aber-
rant enzyme activity, ER stress, mitochondrial dysfunction,
and glial dysfunction contributing to motoneuron death [7].
An added complexity to mSOD pathogenicity is exper-
imental evidence indicating that motoneuron death in the
mSOD model is a noncell autonomous event. Although
mSOD expression restricted to neurons is suﬃcient to
cause motoneuron death if expressed at adequate levels [8],
mSOD expression in surrounding astrocytes and microglia
influences the rate of progression of neurodegeneration.
Experiments in which mSOD expression in microglia was
reduced [9] or ablated [10] prolonged disease duration and
extended survival in mSOD mice but did not aﬀect the
time of disease onset. Similarly, the establishment of wild-
type astroglial pools via the transplantation of astroglial
precursors into the mSOD spinal cord resulted in prolonged
survival in mSOD mice [11]. Notably, restricted mSOD
expression in astrocytes or microglia is not suﬃcient to cause
dysfunction in wild-type neurons [12]. Together these results
suggest that the onset of neurodegeneration in the mSOD
mouse is due to mSOD expression in motoneurons but
that the rate of disease progression is influenced by mSOD
expression in surrounding microglia and astrocytes.
3. Microglia: CNS Resident Macrophages
Within the CNS, populations of macrophages can be dis-
tinguished based on their anatomical location. Perivascular
macrophages lie between the basal lamina of blood vessels
and the glia limitans while meningeal macrophages lie within
the leptomeninges that surround the CNS. Microglia are
considered the CNS tissue-resident macrophage population
and are found within the parenchyma of the CNS. These
cells possess a characteristic stellate morphology, with long
sinuous processes extending from a round cell body. In their
quiescent state, microglia are highly dynamic cells, surveying
their surrounding microenvironment through the constant
extension and retraction of their processes; it is estimated
that the entire extracellular space of the CNS is surveyed
every few hours [13].
The phenotype of resting microglia diﬀers from that
of other populations of tissue macrophages, being more
similar to that of immature myeloid cells; microglia express
only low levels of CD45, major histocompatibility complexes
(MHCs), and are poor antigen presenting cells (APCs; [14]).
The downregulated phenotype ofmicroglia, along with a lack
of a conventional lymphatic system and the segregation of the
brain parenchyma from peripheral blood by the blood-brain
barrier, provides the CNS with a status of immune privilege.
This immune specialization enables the suppression and
strict regulation of immune responses that could damage
surrounding neurons that have only limited regenerative
potential. This should not suggest that the CNS is not im-
mune competent, as foreign pathogens, proinflammatory
cytokines, or neuronal injury induces microglial activation
characterized by morphological alterations including the
retraction and thickening of processes and hypertrophy of
the cell body [15]. Although thesemorphological changes are
stereotypical with regards to microglial activation, as with
other macrophage populations, the phenotype of activated
microglia can be highly variable.
Often likened to a double-edged sword in the literature,
activated microglia can produce substances that are either
beneficial or toxic to surrounding neurons. M1- (classically)
activated microglia exhibit a proinflammatory phenotype
characterized by the production of interleukin- (IL-) 1β and
tumor necrosis factor α (TNF-α) and increased release of
reactive oxygen species and nitric oxide through upregulated
expression of NADPH oxidase and inducible nitric oxide
synthase (iNOS), respectively (Table 1). In vitro, cocul-
tured microglia and neurons treated with lipopolysaccharide
(LPS), a potent stimulus for M1 activation of macrophages,
result in increased microglial production of nitric oxide
(NO) and reactive oxygen species (ROS), as well as increased
levels of extracellular glutamate which culminates in the
excitotoxic death of neurons [16]. Treatment of cultured
microglia using IL-4 results in an M2- (alternatively) acti-
vated phenotype typified by the enhanced expression of
anti-inflammatory cytokines (e.g. IL-10) that dampen
inflammation and lead to the release of neurotrophic
factors (e.g., IGF-1, GDNF) that support neuronal sur-
vival (Table 1). Another feature distinguishing M1 and M2
activation programs is the metabolism of L-arginine; in
M1-activated macrophages and microglia, upregulation of
iNOS converts L-arginine to NO, while in M2-activated
macrophages it converts L-arginine to L-ornithine (Table 1,
[17]).
Neurons play an integral role in regulating microglial
activation by expressing membrane bound and soluble
mediators that enhance microglial production of anti-
inflammatory cytokines and neurotrophins. For example,
CD200 is a glycoprotein expressed by neurons and its cognate
receptor (CD200R) is expressed by all myeloid cells including
microglia. In the CNS of mice deficient for CD200R,
microglia were observed to possess activated morphologies
under steady-state conditions and exhibited an enhanced
response following facial nerve axotomy compared to sim-
ilarly treated wild-type mice [18] suggesting that neuronal
expression of CD200 regulates microglial activation. A sec-
ond example of how neurons regulate microglial function
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Table 1: Macrophage activation programs can be distinguished by
the associated release of cytokines, arginine metabolism, secreted
release of mediators, and antigenicity.
M1 M2
Cytokines released
TNF-α, IL-1β,
IL-6, IL-12,
IL-23
IL-10, IL-4, IL-13,
TGF-β
Arginine metabolism iNOS −→ NO arginase 1−→
L-ornithine
Other secreted
mediators
NO, ROS
Neurotrophics (GDNF,
IGF-1)
Antigenicity IL-1R, CCR7
IL-1Ra, CD150, CD14,
CD163
is through the chemokine fractalkine (CX3CL1) which is
expressed on neuronal cell membranes. Following prote-
olytic cleavage, CX3CL1 is released into the extracellular
milieu and aﬀects microglia exclusively as microglia are
the only cells within the CNS that express the fractalkine
receptor (CX3CR1). CX3CR1−/− mice exhibit dysregulated
microglial responses following peripheral injection of LPS,
while CX3CR1 ablation in mSOD mice results in increased
levels of neuronal loss [19]. Neuronal communication with
microglia keeps inflammatory responses in check, preventing
neuronal damage by aberrantly activated microglia.
4. T Cells
T cells are the central players in adaptive immunity and can
be divided into diﬀerent subsets based on the expression
of cell surface molecules and function (Table 2). Cytotoxic
T cells (CTLs) express CD8 and are capable of inducing
apoptosis in cells through the expression of Fas ligand and
through the exocytosis of perforin and granzymes [20]. The
Fas ligand (CD95L) expressed on CD8+ T cells interacts with
Fas (CD95) expressed on host cells to induce the downstream
activation of caspases, culminating in the apoptosis of host
cells. Perforin induces the formation of pores on the target
cell membrane, which can result in osmotic cell lysis and
provides a means of entry for secreted granzymes [21].
T lymphocytes expressing CD4 include helper T cells
(Th) that are further classified according to cytokine pro-
duction profiles and eﬀector functions and T-regulatory cells
(Tregs; Table 2). Compared to CTLs, CD4+ T cells have
only limited ability to directly kill cells; they do not express
Fas ligand or secrete granulysin and function mainly to
activate and regulate the activity of other cells involved in
the immune response, including macrophages and microglia
[22]. For example, Th1 and Th17 cells can promote M1
macrophage activation through the secretion of the proin-
flammatory cytokines IL-1 and IL-17, respectively, while
Th2 cells secrete cytokines that antagonize proinflammatory
mediators and are capable of skewing macrophage activation
towards an M2 phenotype through the secretion of IL-4
[23]. Regulatory T cells (Tregs) are characterized by the
expression of CD4, CD25, CD62L, CD103, CD152, and the
FoxP3 transcription factor which is essential for obtaining
the Treg phenotype [21]. For each adaptive immune response
launched, a corresponding regulatory response is elicited and
mediated by Treg cells that function to regulate the type and
level of immune activation [23].
Naive T cells are activated upon recognition and binding
of antigen specific to their expressed T-cell receptor; dif-
ferentiation to a specific eﬀector subtype is determined by
the local microenvironment. For CD4+ T cells, antigen is
presented on MHC class II molecules on the membranes of
APCs, typically dendritic cells, and activated macrophages.
CD8+ T cells recognize antigen presented on MHC class
I molecules which are expressed on the membranes of all
nucleated cells with the exception of neurons and other cell
populations within the CNS; however, under neuroinflam-
matory conditions, neurons upregulate their MHC class I
expression, making them potential targets for CTLs [24].
Notably, after the phagocytosis of foreign pathogens or neu-
ronal debris following injury or degeneration, macrophages
can cross-present antigens on MHC class I molecules to
CD8+ T cells, resulting in their activation and potential
reactivity to neuronal cells [20]. Neuronal antigen-specific
CD8+ T cells must first be activated within secondary
lymphoid organs beforemigration and extravasation into the
CNS. This may be accomplished through antigen drainage of
cerebrospinal fluid into the cervical lymphatics or through
the migration of APCs residing in the perivascular space
to lymph nodes [20]. For both CD4+ and CD8+ T cells, a
secondary independent signal elicited through the binding of
molecules present on the membranes of host cells is essential
for activation and clonal expansion; this secondary signal
from APCs may be stimulatory or inhibitory. The types of
costimulatory or coinhibitory molecules expressed by APCs
confer the nature of their functional activation states, while
the density of costimulatory and coinhibitory molecules on
T-cell membranes dictates the functional outcome of T-
cell activation [25]. In the absence of costimulation, T cells
enter a state of anergy and are incapable of activation upon
subsequent antigen recognition by their T-cell receptor [21].
Activated T cells are capable of extravasating into the
CNS where they perform immune surveillance, and in the
steady state, variable numbers of T cells are present within
the parenchyma of the CNS [26]; however, very few if any
CTLs are observed in the healthy CNS [27]. The healthy CNS
parenchyma lacks resident dendritic cell populations but
these cells are present within the meninges and perivascular
spaces [28], and upon activation, microglia increase their
expression of MHC class II molecules, becoming proficient
APCs [29].
Once T cells are present within the extracellular space of
the CNS, resident parenchymal cells including microglia and
neurons are capable of mediating T-cell responses through
cell-cell contact, representing a further source of protection
from rogue immunological responses. All cells within the
parenchyma of the CNS constitutively express Fas-ligand,
which upon contact with activated Fas-expressing CD8+ T
cells surveying the CNS for their cognate antigen, induces
the CD8+ T-cell apoptosis [30]. Microglia are also capable
of modulating T-cell responses as they constitutively express
B7 homolog 1 (B7-H1) and increase their expression in the
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Table 2: The categorization of T cells into subsets is based on cell antigenicity, cytokine profile, and eﬀector function.
Antigenicity Cytokine profile Eﬀector function
Th1 CD4+ IL-2, TNF-α, IFN-γ M1 macrophage activation
Th2 CD4+ IL-4, IL-10, IL-6, IL-13 Downregulation of M1 macrophage activation
Th17 CD4+ IL-17 M1 macrophage activation
Treg CD4+CD25+FoxP3+ IL-4, IL-10, TGF-β Damping of proinflammatory response
CTL CD8+ TNF-α, IFN-γ Elimination of infected cells
presence of proinflammatory cytokines IL-1 and interferon-γ
(IFN-γ; [31]). B7-H1 interacts with the programmed-death
receptor 1 (PD-1) expressed on T cells, inhibiting T-cell acti-
vation and cytokine secretion [20]. These factors contribute
to CNS-associated immune privilege by preventing aberrant
inflammatory reactions and the consequent neuronal injury
they could impart.
5. Neuroinflammatory Response
in the mSOD Mouse Model of ALS
Neurodegenerative diseases including Parkinson’s disease,
AD, and ALS are characterized by the death of specific
populations of neurons accompanied by a neuroinflamma-
tory response that is characterized by microglial activation
and T-cell infiltrates being at aﬀected regions. Significant
levels of microgliosis have been observed in the spinal cord
of ALS patients at autopsy, with T-cell infiltrates found
in close proximity to the corticospinal tract [32, 33] as
well as in other aﬀected brain regions [34]. Histological
examination of CNS tissue from ALS patients is typically
limited to advanced stages of disease. However, studies
using PET scanning and other imaging techniques permit
evaluation of ALS patients at various stages of their disease.
Turner et al. [35] administered the radioligand [11C]-(R)-
PK11195 to ALS patients, which binds the translocator
protein (formerly known as the peripheral benzodiazepine
receptor) that is highly expressed on mitochondria of acti-
vated, but not resting microglia. This enabled PET detection
of cerebral microglial activation in vivo over the disease
course. Widespread microglial activation was observed in
the motor cortex, pons, dorsolateral prefrontal cortex, and
thalamus where the extent of microgliosis was positively
correlated with the severity of ALS [35].
Notably, patients suﬀering from sporadic ALS have been
reported to have increased levels of circulating inflamma-
tory (CD16+) monocytes in peripheral blood [36], which
correlated well with increased levels of plasma LPS [37],
a potent inducer of M1 activation in macrophages. These
results indicate that the inflammatory response associated
with ALS is not limited to the CNS, with systemic immune
activation also being observed and potentially influencing
disease progression. Furthermore, recent reports by Swarup
et al. demonstrated that mRNA levels of TDP-43 and the p65
subunit of nuclear factor κB (NF-κB), a transcription factor
involved in the expression of proinflammatory mediators,
are upregulated in the spinal cords of ALS patients [38].
When cultured microglia engineered to overexpress TDP-43
were treated with LPS, increased levels of proinflammatory
cytokines and neurotoxic factors were produced compared
to wild-type microglia [38]. Together, the increased levels of
plasma LPS and TDP-43 observed in ALS patients indicate
widespread inflammation and suggest that modulation of
the inflammatory response may represent an avenue of
therapeutic intervention.
As themSODmousemodel recapitulates many aspects of
the neuroinflammatory response observed in ALS patients,
this model enables an in-depth analyses of neuroinflam-
mation at diﬀerent stages of disease. In the mSOD mouse,
increased numbers of activated microglia are observed at
early presymptomatic stages of disease, and with disease
progression to end-stage, microglial numbers in the lumbar
spinal cord increase further by nearly 2-fold [39, 40].
Increased numbers of T cells are found in the lumbar spinal
cord of mSOD mice beginning at presymptomatic stages
and increasing with disease progression to symptomatic
and disease end-stage, where T-cell numbers are 10-fold
higher than of controls (Lewis unpublished data; [40, 41]).
Phenotypical analysis indicated that T cells populating the
mSOD spinal cord were limited to the CD4+ subsets until
disease end-stage at which point 40% of T cells were CD8+
CTLs ([41]; Lewis unpublished data).
Although neuroinflammation is often considered a con-
sequence rather than a cause of neurodegeneration in ALS
patients and in the mSOD mouse model, several studies have
demonstrated that modulation of the inflammatory response
in mSOD mice alters disease progression [40–44]. Given that
reports that anti-inflammatory drugs including minocycline
slowed the rate of disease progression and extended survival
times in mSODmice [42–44] and because mSOD-expressing
microglia exhibit enhanced neurotoxicity when treated with
LPS [45], it was postulated that microgliosis in the mSOD
mouse contributed to motoneuron degeneration. However,
experiments in which the proinflammatory cytokine TNF-α
was ablated in mSOD mice [46] or where the proliferation
of microglia was blocked [47] had no eﬀect on the rate of
disease progression, suggesting that microgliosis does not
exacerbate neurodegeneration in the mSOD mouse mode.
While previous research has focused on the potential
neurotoxicity of activated microglia in the mSOD mouse
model, recent work has raised the hypothesis that activated
microglia might confer neuroprotection. Phenotypical anal-
ysis of microglia in mSODmice using RT-PCR demonstrated
that the expression of the neurotrophic factor IGF-1 by
microglia increased with disease progression, as did the ex-
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pression of the anti-inflammatory IL-1R antagonist which
binds to the IL-1 receptor, blocking IL-1 binding and
downstream proinflammatory signalling; levels of the proin-
flammatory cytokine TNF-α did not change with disease
progression [40]. Recent work by Beers et al. [48] supports
a neuroprotective role for microglia until the end-stage of
disease, at which point levels of proinflammatory cytokine
IL-1β and TNF-α increase, as do levels of NADPH oxidase
[48]. These observations suggest that during initial stages
of disease in mSOD mice, microglia exhibit an M2 pheno-
type supporting neuronal survival. However, as the disease
advances, microglial activation becomes skewed towards
an M1 phenotype, although the physiological mechanisms
eliciting this switch in activation have not been elucidated.
Investigations into the role of T cells in neuroinflam-
mation in the mSOD mouse suggest that these cells influ-
ence the phenotypic profile of activated microglia. In two
independent studies, ablation of T cells in mSOD mice was
achieved by crossing these mice with a TCR−/− strain [40]
or with an RAG2−/− strain [41], and disease progression
was accelerated in the mSOD mice [49]. In both studies,
microglial morphological activation in mSOD mice lacking
functional T cells was reduced; however, levels of M1
functional markers such as TNFα and iNOS were increased
while markers of alternative activation such as IGF-1, GDNF-
1, TGF-B, and IL-4 were reduced [41]. To further identify
which T-cell subsets were capable of aﬀecting disease course,
the mSOD mice were crossed onto a strain lacking only
functional CD4+ T cells [41]. The observed result was similar
to that demonstrated by the studies in which all T cells were
ablated, indicating that CD4+ T cells in the mSOD spinal
cord function to modulate microglial activation and skew
it towards an M2 neuroprotective phenotype [41]. Banerjee
et al. [50] further refined these observations by comparing
the eﬀects of adoptive transfer of activated CD4+CD25+ Treg
cells and CD4+CD25− Teﬀ cells harvested from wild-type
mice on disease progression in mSOD mice. The transfer of
Treg cells delayed disease onset while transfer of Teﬀ cells
prolonged disease progression and the duration of survival
[50]. Notably, CD8+ T cells have not been observed inmSOD
spinal cord until disease end-stage (Lewis unpublished
data; [40]), a time point that corresponds temporally with
reduced numbers of CD4+CD25+ and CD25+ Treg cells in
mSOD spinal cord and the skewing of microglial phenotypes
towards M1 activation [48].
Findings from these studies suggest that exploiting the
neurotrophism of alternatively activated microglia, rather
than dampening microglial activation generally, may have
some therapeutic benefit in ALS; however, molecular targets
enabling this manipulation remain elusive. Recently Beers
et al. [51] demonstrated that the passive transfer of CD4+
Tregs into mSOD mice extended the stable phase of disease
progression and survival times, suggesting that manipulation
of the microglial response through the adoptive transfer
of Treg cells or pharmaceutical agents that potentiate M2
activation in microglia may have therapeutic value. In fact,
Neuraltus Pharmaceuticals (Palo Alto, CA) is currently
conducting phase II clinical trials in patients suﬀering from
ALS, PD, and AD using NP100, a pharmaceutical drug
designed to skew macrophage activation towards an M2
phenotype to determine its eﬃcacy in prolonging disease
duration.
6. A Role for Bone-Marrow-Derived Microglia
Pharmacological treatments for ALS have largely been in-
eﬀective at slowing the disease process, in part because
the blood-brain barrier prevents the transmission of the
majority of drugs from the blood into the CNS. This has
spurred investigations into alternative therapeutic modalities
for the treatment of ALS and other neurodegenerative dis-
eases. Microglia are members of the mononuclear phagocyte
system which also includes hematopoietic progenitors, blood
monocytes, dendritic cells, and other populations of tissue
macrophages [52]. Under inflammatory conditions and to a
lesser extent during the steady state, circulating monocytes
are recruited to tissue compartments where they extravasate
and diﬀerentiate intomacrophages. Although it has been well
established that macrophage populations in nonneuronal
tissues are maintained to a variable degree through the
recruitment of monocytes [53], evidence indicates that only
under certain conditions myeloid cells contribute to the
maintenance of microglial populations. This highlights the
potential for these cells to function as vehicles to transport
neurosupportive substances into the diseased CNS.
Investigations into the migration of bone-marrow-
derived cells (BMDCs) into the CNS often employ bone
marrow (BM) chimeric mice, typically created by exposing
rodents to myeloablative levels of radiation followed by
the adoptive transfer of labelled BM cells. The results of
these studies suggest that while BMDCs contribute to the
maintenance of meningeal and perivascular macrophage
populations within the CNS, BMDCs make only limited
contributions to the parenchymal microglial pool [54–57].
However, in BM chimeric models of neurodegenerative
disease including PD, AD, and ALS, increased numbers
of BMDCs are observed at sites of neurodegeneration,
suggesting BMDCs home to and/or expand at aﬀected sites.
A caveat associated with the irradiation-BM reconstitu-
tion protocol employed to create BM-chimeric mice is that it
introduces two confounding variables. First, irradiation elic-
its a widespread inflammatory response including increased
levels of cytokines and chemokines within the CNS [58] and
has been shown to induce apoptosis of endothelial cells in the
rat spinal cord-blood barrier [59]. Secondly, the injection of
whole BM into the circulation of mice introduces BM pro-
genitor populations into the blood that would under normal
physiological circumstances not enter the circulation [60].
Indeed, studies employing chimeric mice created through
parabiosis, a surgical technique in which the vascular systems
of two genetically distinct mice are joined, demonstrated
that in the absence of irradiation and the injection of
BM precursor populations into the circulation, BMDCs do
not appreciably accumulate within the healthy CNS, or in
models of neuronal injury and neurodegenerative disease
[58, 60, 61]. Recent work by Ajami et al. [62] suggests that
in irradiated BM-chimeric mice, hematopoietic precursors
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contribute to microglial populations while blood mono-
cytes infiltrating the CNS during experimental autoimmune
encephalitis (EAE) in chimeric mice represent a transient
population of CNS-associated macrophages that turnover
upon disease resolution. Therefore, in order to improve
the clinical potential of BMDCs as treatment vehicles in
neurodegenerative disease, the cell populations within BM
capable of infiltrating the CNS and contributing tomicroglial
pools and factors enabling this migration must be identified.
7. Conclusion
Once considered a consequence of neuron death in chronic
neurodegenerative disease, neuroinflammation is now rec-
ognized to influence disease progression in ALS and the
mSOD mouse model. While microglial activation and T-cell
infiltration have previously been implicated in exacerbating
pathological processes and contributing neuron death in
the mSOD mouse, experimental evidence has demonstrated
that microglial activation together with the infiltration
of instructive T cells has trophic eﬀects on surrounding
neurons until late stages of disease. Further investigations
into phenomena that induce this phenotypical switch in
activated microglia could potentially enable the exploitation
of microglial neurotrophism and provide future therapeutic
benefits.
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